Skip to main content
HANS BIOMED CORPORATION logo

HANS BIOMED CORPORATION — Investor Relations & Filings

Ticker · 042520 ISIN · KR7042520007 KO Manufacturing
Open in API
Filings indexed 232 across all filing types
Latest filing 2026-05-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 042520

About HANS BIOMED CORPORATION

http://www.hansbiomed.com/en/

HANS BIOMED CORPORATION is a biotechnology company that develops, manufactures, and sells high-tech medical materials, devices, and biologics. The company's core focus is on regenerative medicine and tissue engineering. Its product portfolio includes silicone breast implants, allograft tissue products for skin and bone grafts, and absorbable lifting sutures for aesthetic procedures. The company also offers professional cosmeceutical products. HANS BIOMED supports its operations through a dedicated tissue engineering research laboratory and a human tissue bank, aiming to provide innovative solutions for the global medical and aesthetic markets.

Recent filings

Filing Released Lang Actions
반기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled ‘반기보고서 (제28기)’ covering the six‐month period 2025.10.01–2026.03.31, and contains full financial tables, operational and business overviews, production and sales data. This corresponds to a half-year interim report with substantive financial statements, fitting the definition of an Interim/Quarterly Report. H1 2026
2026-05-14 Korean
기업설명회(IR)개최
Investor Presentation Classification · 95% confidence The document is an announcement of an upcoming investor presentation (IR) event scheduled for May 21, 2026. It includes details such as date, time, location, target audience, purpose, and contact information. The content focuses on informing about the event rather than providing the actual presentation or financial data. The document length is short (864 characters), and it does not contain substantive financial statements or analysis. Therefore, it fits the category of an Investor Presentation announcement rather than the presentation itself or a financial report.
2026-05-08 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서(약식)' which translates to 'Report on Large Shareholding Status (Abbreviated)'. It details the shareholding changes of KB Asset Management Co., Ltd. in Hans Biomed Co., Ltd. It includes specific dates, share quantities, ownership percentages, and transaction details. The content is focused on reporting changes in significant share ownership levels, consistent with regulatory requirements for major shareholding notifications. There is no indication of financial performance data, management discussion, or other report types. The document is not an announcement of a report but the report itself, given its length and detailed data. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2026-05-04 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 95% confidence The document is a Korean “주식등의 대량보유상황보고서(약식)” – a report of large shareholdings, detailing changes in share counts and percentages by the reporting entity and its affiliates. This corresponds to a Major Shareholding Notification, reporting crossing threshold and changes in substantial holdings. Therefore, it matches the MRQ category.
2026-04-09 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details the shareholding changes of KB Asset Management in Hans Biomed Co., Ltd. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks changes in significant ownership levels.
2026-03-03 Korean
분기보고서 (2025.12)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for HansBiomed Corp, covering the period from October 1, 2025, to December 31, 2025. It contains detailed financial data, business operations, management information, and capital structure, which aligns with the definition of an Interim/Quarterly Report (IR). Q4 2025
2026-02-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.